Home > 5-HT Receptor & Adrenergic Receptor & 5-HT Receptor & Adrenergic Receptor  & Histamine Receptor & Histamine Receptor & > Mirtazapine

Mirtazapine

米氮平,米尔塔扎平,Org3770,Org-3770,Org 3770

Mirtazapine是抗抑郁的5-HT受体抑制剂。

目录号
EY0330
EY0330
EY0330
EY0330
纯度
99.23%
99.23%
99.23%
99.23%
规格
5 mg
25 mg
50 mg
100 mg
原价
265.00
665.00
990
1400
售价
265.00
665.00
990
1400
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Mirtazapine is an adrenergic and seroton receptor antagonist, used to treat depression.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Carolina Muguruza et. Al. Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment. Neuropharmacology, 86, (2013).
    [2] Maho Okubo et. Al. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients. Biochemical Pharmacology, 93(1), 104-109 (2015).
    [3] Reka A Otvos et. Al. Development of Plate Reader and On-Line Microfluidic Screening to Identify Ligands of the 5-Hydroxytryptamine Binding Protein in Venoms. Toxins, 7(7), 2336-2353 (2015)

    分子式
    C17H19N3    		 分子量
    265.35    		 CAS号
    85650-52-8     		储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    20 mM    		 Water
    <1 mg/mL    		 Ethanol
    50 mM

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT00449189 PTSD Drug: Mirtazapine|Drug: Placebo Tuscaloosa Research & Education Advancement Corporation Phase 4 2006-10-01 2012-08-30
    NCT01601002 Major Depressive Disorder Drug: Mirtazapine Lawson Health Research Institute Phase 4 2012-06-01 2016-04-20
    NCT01240096 Functional Dyspepsia Drug: Mirtazapine Universitaire Ziekenhuizen Leuven Phase 4 2006-09-01 2010-11-12
    NCT00878540 Healthy Drug: mirtazapine Max-Planck-Institute of Psychiatry Phase 1 2008-09-01 2010-09-15
    NCT01039740 Depression Drug: Mirtazapine Samsung Medical Center 2003-02-01 2015-12-30
    NCT00832520 Advanced Cancer Drug: Remeron (mirtazapine) New Mexico Cancer Care Alliance Phase 2 2008-11-01 2015-06-16
    NCT01867775 Alzheimer's Disease|Sleep Disorders Drug: Mirtazapine Brasilia University Hospital Phase 3 2012-05-01 2013-06-03
    NCT01949571 Drug-withdrawal.|Drug Abuse|Drug-induced Depressive State|AOD Craving|AODR Depressive State Drug: Mirtazapine (REMERON, Schering-Plough-Organon) Instituto Nacional de Psiquiatr铆a Dr. Ram贸n de la Fuente Phase 2 2007-01-01 2013-09-20
    NCT00322309 Cocaine Dependence|Depression Drug: Mirtazapine (Remeron) Boston University Phase 2 2005-09-01 2010-08-30
    NCT00919295 Fibromyalgia Syndrome Drug: mirtazapine|Drug: placebo Mahidol University|University of Texas|University of Wuerzburg Phase 2 2008-12-01 2012-07-24
    NCT02185131 Major Depressive Disorder|Alcohol Use Disorder Drug: Mirtazapine|Drug: Placebo University of Pittsburgh|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2013-09-01 2016-01-07
    NCT02650544 Carcinoma, Non-Small-Cell Lung|Depression Drug: Mirtazapine|Drug: Placebo Sun Yat-sen University Phase 2 2015-12-01 2016-01-06
    NCT00600145 Amphetamine Dependence Drug: Mirtazapine|Other: Placebo University of Virginia|American Association of Chairs of Departments of Psychiatry 2007-09-01 2011-04-26
    NCT01263080 Schizophrenia Drug: mirtazapine|Drug: folic acid placebo|Drug: mirtazapine placebo|Drug: folic acid Capital Medical University Phase 4 2010-11-01 2016-08-01
    NCT00497081 Substance Abuse|HIV Infections Drug: mirtazapine|Drug: placebo San Francisco Department of Public Health|National Institute on Drug Abuse (NIDA)|Public Health Foundation Enterprises, Inc. Phase 2 2007-05-01 2014-12-12
    NCT00865384 Healthy Drug: Mirtazapine 15 mg tablets, single dose|Drug: REMERON庐 15 mg tablets, single dose Actavis Inc. Phase 1 2001-09-01 2010-08-13
    NCT01465919 Depression Drug: Mirtazapine|Other: Supportive psychotherapy Seoul National University Boramae Hospital Phase 4 2011-08-01 2016-04-16
    NCT00302107 Anxiety|PTSD Drug: Mirtazapine|Drug: Placebo VA Office of Research and Development Phase 4 2006-04-01 2014-11-25
    NCT00249444 Cocaine Dependence|Depression Drug: Mirtazapine|Drug: Placebo New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA) Phase 2 2006-05-01 2013-10-29
    NCT00865696 Healthy Drug: Mirtazapine 15 mg tablets, single dose|Drug: REMERON庐 15 mg tablets, single dose Actavis Inc. Phase 1 2001-09-01 2010-08-13

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：